相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
Tomohiko Narita et al.
JOURNAL OF DERMATOLOGY (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Ipilimumab-Induced Adrenalitis A Possible Pitfall in 18F-FDG-PET/CT
Sara Bacanovic et al.
CLINICAL NUCLEAR MEDICINE (2015)
Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
Steven Orlov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
J. Gao et al.
ONCOGENE (2015)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Jason J. Luke et al.
ONCOTARGET (2015)
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
Sree Harsha Tirumani et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
Jing Lu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Immune Checkpoint Blockade
Jarushka Naidoo et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati et al.
ONCOTARGETS AND THERAPY (2014)
Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
Le Min et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
Joke Marlier et al.
ENDOCRINE (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Francesco Torino et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
PD-1 is a novel regulator of human B-cell activation
Marie-Laure Thibult et al.
INTERNATIONAL IMMUNOLOGY (2013)
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Salvatore Maria Corsello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Francesco Torino et al.
THYROID (2013)
Ipilimumab-induced autoimmune adrenalitis
Le Min et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
ASSOCIATION OF IPILIMUMAB THERAPY FOR ADVANCED MELANOMA WITH SECONDARY ADRENAL INSUFFICIENCY: A CASE SERIES
Le Min et al.
ENDOCRINE PRACTICE (2012)
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
Agata Juszczak et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Thyroid Dysfunction from Antineoplastic Agents
Ole-Petter Riksfjord Hamnvik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Gary Borodic et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2011)
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis
Xin Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Corticotropin Tests for Hypothalamic-Pituitary-Adrenal Insufficiency: A Metaanalysis
Rasa Kazlauskaite et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
AV Maker et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autoimmune hypophysitis
P Caturegli et al.
ENDOCRINE REVIEWS (2005)
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells
XB Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
